|
KMID : 0882420190940030303
|
|
Korean Journal of Medicine
2019 Volume.94 No. 3 p.303 ~ p.307
|
|
|
Infliximab-Induced Lupus in Crohn’s Disease
|
|
Choi Su-Jin
Kim So-Hyun
Kim Hye-Yeong
Lee Yong-June
Hwangbo Hyun
Yang Suk-Kyun
Kim Yong-Gil
|
|
|
Abstract
|
|
|
|
Infliximab (IFX) is an anti-tumor necrosis factor (TNF) monoclonal antibody used to treat rheumatoid arthritis, ankylosing spondylitis, and Crohn’s disease. Rarely, anti-TNF-induced lupus (ATIL) may occur. ATIL differs from classical drug-induced lupus. We report a 49-year-old woman who developed polyarthralgia after 2 years of IFX treatment for Crohn’s disease. Based on the autoantibody profiles, ATIL was diagnosed and low-dose glucocorticoid, hydroxychloroquine, and celecoxib were prescribed. However, arthralgia and hemolytic anemia developed. Because the anti-dsDNA titers waxed and waned, she was switched to vedolizumab, a monoclonal antibody to the human lymphocyte α4β7 integrin. Six months after switching treatment, the arthralgia had improved and the anti-dsDNA antibody normalized. Here, we report a case of ATIL that resolved after switching from infliximab to vedolizumab.
|
|
|
KEYWORD
|
|
|
Infliximab, Lupus erythematosus, Systemic, Crohn disease
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
  
|
|